相关实验视频

Updated: Jan 12, 2026

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

针对低度质瘤患者的新兴疗法

Katherine B Peters¹

¹The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC, 27710, USA. katherine.peters@duke.edu.

|November 7, 2025

概括

新的向疗法为低度质瘤患者提供了希望. 最近的批准包括儿童病例的BRAF抑制剂组合和成人IDH抑制剂治疗,改变了脑瘤治疗.

科学领域:

神经瘤学神经瘤学
分子遗传学分子遗传学
翻译医学是一种翻译医学.

背景情况:

低级质瘤 (世卫组织2级) 是一种主要的脑瘤,影响儿童和成人.
传统治疗反映了更高度的质瘤,缺乏特异性.
2021年世卫组织分类根据分子形状改进了基于分子形状的诊断.

研究的目的:

审查低度质瘤的分子和遗传基础.
突出针对性治疗的进展.
讨论FDA批准的针对特定遗传突变的向治疗方法.

主要方法:

关于低级质瘤遗传学和向治疗的科学文献的综述.
对儿科 (MAPK通路) 和成人 (IDH突变) 质瘤的分子变化的分析.
对 FDA 对新型向药物的批准进行审查.

主要成果:

儿科质瘤经常存在MAPK路径的改变 (例如,BRAF突变).
成人扩散性质瘤的特征是IDH突变.
达布拉费尼布/特拉美丁尼布,托沃拉费尼布和沃拉西迪尼布等向疗法已经获得了FDA的批准.

结论:

向疗法代表了低度质瘤治疗的范式转变.
了解分子驱动因素对于有效的治疗策略至关重要.
需要进一步的研究来整合这些疗法并评估长期结果.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...